Cambridge cancer drug firm Blueprint raises $125 million in new offering
Cambridge-based Blueprint Medicines, responsible for one of the biggest biotech IPOs in recent years, said late Wednesday that it had raised $125 million in a new stock offering.
The cancer drug developer offered five million shares at a price of $25 ' a discount of about five percent from the closing price on Wednesday ' while giving underwriters an opportunity to purchase an additional 750,000 shares. As of Thursday at 11:00 a.m., the shares were up nearly six percent, at $27.72 per share.
Blueprint...